Nonlinear Enter Co-Marketing Agreement with Agilent
News May 11, 2006
Nonlinear Dynamics Ltd has announced a co-marketing agreement with Agilent Technologies Inc. to mutually promote and distribute integrated analysis solutions.
The agreement is centred on synergies between the Agilent 2100 bioanalyzer ‘lab-on-a-chip’ platform and Nonlinear’s TL120 DM software.
The first stage of the agreement will see technical development to automate the export of electropherogram data from Agilent’s bioanalyzer Expert software for analysis with Nonlinear’s TotalLab TL120 DM for the purpose of varietal identification.
This collaborative solution will enable researchers to import DNA, RNA and protein sample data from the 2100 bioanalyzer for further relationship comparison, archiving and data mining within TL120 DM.
Fred Strohmeier, General Manager of Agilent Technologies Liquid Phase Analysis Business, said, "Recognising the evolutionary challenges facing life science researchers to analyse, store and mine increasing volumes of RNA, DNA and assay data, we are pleased to be working with Nonlinear to enable users to discover more using the bioanalyzer platform."
"Our product portfolio also incorporates the applications of mass spectrometry, microarrays, gas and liquid chromatography."
"Because Nonlinear already has various technologies available for use in these markets, there is potential for further collaboration in the future."
Will Dracup, Group CEO of Nonlinear Dynamics, said, "Agilent’s reputation as the world’s leading measurement company, coupled with the natural synergy between the Bioanalyzer and TotalLab platform, makes them an excellent partner."
"Users will benefit from the application of independently developed, industry-tested hardware and software combined for the first time as a powerful integrated solution."
Mechanism Controlling Multiple Sclerosis Risk IdentifiedNews
Researchers at Karolinska Institutet have now discovered a new mechanism of a major risk gene for multiple sclerosis (MS) that triggers disease through so-called epigenetic regulation. They also found a protective genetic variant that reduces the risk for MS through the same mechanism.
Synthetic DNA Shuffling Enzyme Outpaces Natural CounterpartNews
A new synthetic enzyme, crafted from DNA rather than protein, flips lipid molecules within the cell membrane, triggering a signal pathway that could be harnessed to induce cell death in cancer cells. Researchers say their lipid-scrambling DNA enzyme is the first in its class to outperform naturally occurring enzymes – and does so by three orders of magnitudeREAD MORE
Antarctic Worm and Machine Learning Help Identify Cerebral Palsy EarlierNews
A research team has released a study in the peer-reviewed journal BMC Bioinformatics showing that DNA methylation patterns in circulating blood cells can be used to help identify spastic cerebral palsy (CP) patients. The technique which makes use of machine learning, data science and even analysis of Antarctic worms, raises hopes for earlier targeted CP therapies.